公司同时开发其他多款具备先进技术的在研产品，包括创新性的经导管二尖瓣修复夹持系统JensClip及有望成为全球首款使用瓣叶修补技术修复二尖瓣的经导管二尖瓣修复产品MitraPatch等。According to the disclosure of the Hong Kong Stock Exchange on June 21, Ningbo Jianshi Technology Company submitted an application for listing on the main board of the Hong Kong Stock Exchange, with China International Capital Corporation and Citigroup as co-sponsors, Zhitong Financial APP learned.
Jianshi Technology is a medical device company dedicated to developing innovative products for the treatment of structural heart disease. According to Frost Sullivan, the company's core product, LuX-Valve, is expected to be the first transcatheter tricuspid valve replacement approved for commercialization in the world. Another core product of the company, Ken-Valve, is designed for the treatment of severe aortic regurgitation (or associated with aortic stenosis).
The company also develops a number of other products under development with advanced technology, including the innovative transcatheter mitral valve repair clamp system JensClip and MitraPatch, which is expected to be the world's first transcatheter mitral valve repair using valvular repair technology.
The prospectus reveals that as of June 15, 2021, the company's product line has a total of ten products under research. The R & D expenses incurred by the Company in 2019, 2020 and the three months ended March 31, 2021 were RMB 23.2 million, 170.6 million and 19.2 million respectively. The company has 81 authorized patents and 113 patent applications. Specifically, with regard to the core products LuX-Valve and Ken-Valve, the company has 11 and 4 authorized patents and 9 and 0 pending patent applications respectively.
The company has not made a profit and incurred a net loss during the track record period. In 2019, 2020 and the three months ended 31 March 2021, the company recorded net losses of $27.9 million, $299.7 million and $56.5 million respectively. The vast majority of the operating losses come from R & D expenses and administrative expenses (including equity-based share compensation expenses).
